Cheryl Ho, MD, FRCP(C)

Clinical Assistant Professor of Medicine, UBC
Medical Oncologist, BC Cancer Agency
Vancouver, BC

Cheryl Ho is a clinical assistant professor at the University of British Columbia and a medical oncologist at the British Columbia Cancer Agency.

She is currently the provincial systemic chair for head and neck malignancies.

She completed medical school and internal medicine training at the University of Western Ontario.

She is a graduate of the BC Cancer Agency Medical Oncology program and completed a fellowship in Thoracic Oncology at University of California, Davis.

Her current practice focuses on the treatment of thoracic and head and neck malignancies.

Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer Agency
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist at the British Columbia Cancer Agency.
She graduated from medical school at the University of Manitoba and did a residency in internal medicine at the University of British Columbia.

She is currently a medical oncologist at the BC Cancer Agency with clinical interests in GI and respiratory malignancies.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.


Houda Bahig, MD, PhD (c), FRCPC

Radiation Oncologist,
Centre Hospitalier de l’Université de Montréal (CHUM)
Montreal, QC

Houda Bahig is a radiation oncologist and clinician scientist at the Centre Hospitalier de l’UnIversité de Montréal. After receiving her medical degree from McGill University, she carried out her radiation oncology residency at Université de Montréal. She pursued a PhD in Biomedical Sciences focused on the development of new applications of dual energy/dual source computed tomography imaging in radiotherapy planning. She is currently completing a fellowship at MD Anderson Cancer Center centered on the clinical integration of magnetic resonance-guided radiotherapy.

Her clinical practice focuses on lung stereotactic ablative radiotherapy and head and neck cancers. Her current research interests revolve around the incorporation of novel imaging methodologies in radiotherapy aiming at improving outcome prediction and decreasing treatment-related toxicities.

Ronald Burkes, MD, FRCPC

Professor of Medicine, University of Toronto
Staff Medical Oncologist
Mount Sinai Hospital/Princess Margaret Hospital/UHN
Toronto, ON

Ron Burkes is Professor of Medicine at The University of Toronto and staff medical oncologist at Mount Sinai Hospital/Princess Margaret Hospital/University Health Network in Toronto.

He was the program director for the medical oncology training program at the University of Toronto from 1996 to 2005 and director of the Clinical Teaching Unit at PMH from 1999 to 2005. He has won numerous teaching awards including departmental and university wide awards on 13 occasions, the Anderson Award in Program Development and the Hasselback Teaching Award at PMH. He has presented at many local, provincial, national and international meetings.

His research interests include lung and GI malignancies and he has numerous publications including 76 peer reviewed, 126 non-peer reviewed and 2 book chapters.

Jenn Bos, RN

Registered Nurse, Tom Baker Cancer Agency
Calgary, AB

Jenn Bos is currently a registered nurse in systemic day care unit at Tom Baker Cancer Agency. She has 8 years experience in this specialty in British Columbia Cancer Agency (BCCA), Vancouver Center and TBCC. Her current practice focuses on systemic therapy for solid tumor and hematological malignancies.

D. Ross Camidge, MD, PhD

Professor of Medicine/Oncology,
Joyce Zeff Chair in Lung Cancer Research, University of Colorado|
Denver, CO

Dr. Camidge is the Director of Thoracic Oncology at the University of Colorado. His focus is in Thoracic Malignancies and Developmental Therapeutics (Phase I studies). Dr Camidge is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) and a member of the National Comprehensive Cancer Network (NCCN) Lung Cancer, Mesothelioma and Thymic Cancer Committees.

Dr. Camidge has been principal investigator on numerous clinical trials in early phase drug development and thoracic malignancies. He has authored more than 150 articles and reviews in peer-reviewed journals such as Cancer, Journal of Clinical Oncology, Journal of Thoracic Oncology and The New England Journal of Medicine. His work has repeatedly helped to change the standard of care in the treatment of lung and other thoracic cancers. He has presented his research at multiple national and international scientific meetings.

Martin Robert Chasen, MBChB, FCP(SA), MPhil(Pall Med)

Associate Professor, Division of Palliative Care, University of Ottawa
Medical Director, Palliative Care,
William Osler Health System
Medical Director, Palliative Rehabilitation, Élisabeth Bruyère Hospital
Brampton, Ontario

Dr. Martin Chasen is currently the Medical Director of Palliative Care, at William Osler Health System in Brampton. He was previously Medical Director, Palliative Care, at The Ottawa Hospital Cancer Centre and the Palliative Rehabilitation Program at Élisabeth Bruyère Hospital, Ottawa.

Dr. Chasen, born in Pretoria, South Africa completed his undergraduate training in medicine and surgery at the University of Pretoria in 1983, later obtaining a specialist degree in Internal Medicine and Medical Oncology and Master of Philosophy (Palliative Medicine) at the University of Cape Town, South Africa. He is a founding member of the palliative care working group European Society of Medical Oncology and faculty member of ESMO education. In 2009, Dr. Chasen, was Team Leader and Physician, Cancer Nutrition & Rehabilitation Program at McGill University Hospital Complex obtained “Supra regionale de niveau 3” status for the PQCCC.  In 2013, Dr. Chasen and the team at Ottawa Hospital cancer centre achieved ESMO Designated Centre of Integrated Oncology and Palliative care.

He currently holds professorships at the Universities of Toronto, McMaster, Ottawa and McGill. He recently received the Elizabeth J Latimer Prize in Palliative Care from Mc Master University.

He has in excess of 100 peer reviewed publications, abstracts and book chapters. Dr. Chasen is the principle investigator of CIHR (Canadian Institutes of Health Research). This MENAC (The Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia), trial will investigate the addition of the multimodal intervention for patients receiving standard chemotherapy for metastatic cancer. He was also one of the chief investigators for the initial clinical trials on the use of Rolapitant-a novel NKI inhibitor in the treatment of chemo therapy induced nausea and vomiting.

Dr. Chasen has lectured nationally and internationally on rehabilitation of patients with cancer, approaches to treatment of patients with cachexia, chemotherapy induced nausea and vomiting, survivorship and symptom relief.

Dr Chasen was the Regional Palliative care physician lead for Palliative Care- Champlain LHIN from 2009-2015 and is presently the Medical co-lead for the Palliative Care Network in the Central West LHIN.

Parneet K. Cheema, HBSc, MD, MBiotech, FRCPC

Medical Oncologist, William Osler Health System
Assistant Professor, University of Toronto
Toronto, ON

Dr. Parneet Cheema is a medical oncologist at the William Osler Health System at the Brampton and Toronto sites. She is an Assistant Professor with the Department of Medicine at the University of Toronto with a focus in quality improvement. Dr. Cheema completed her undergraduate medical training at the University of Calgary, followed by Internal Medicine and medical oncology training at the University of Toronto. Dr. Cheema also completed a Master’s degree in Biotechnology from the University of Toronto.  She has been an investigator for numerous immunotherapy and targeted therapy clinical trials in the areas of melanoma and lung cancer, and a member of the steering committee for global lung cancer trials, in addition to contributions to national consensus statements. She is also involved in health technology assessments as a previous voting member for the Ontario Steering Committee for Cancer Drugs and currently a member of the clinical guidance panel for the pan-Canadian Oncology Drug Review. Her research focuses on the safe and efficient implementation of advances in personalized medicine in lung cancer and immunotherapy into day-to-day clinical practice.

Pat Croskerry MD, PhD, FRCP(Edin)

Professor of Emergency Medicine and Director, Critical Thinking Program
Dalhousie University
Halifax, NS

His research is principally concerned with clinical decision-making, especially the processes that lead to diagnostic failure.

He is senior editor on a major text Patient Safety in Emergency Medicine published in 2009, and senior author of the recently published Diagnosis: Interpreting the Shadows (2017).

He was appointed to the US Institute of Medicine Committee on Diagnostic Error in Medicine in 2014.

He was nominated to the Canadian Association of Emergency Physicians Top Ten List of most impactful Canadian medical educators in 2016.

Suzanne Drodge M.D., FRCPC

Radiation Oncologist, Eastern Health
Assistant Professor, Faculty of Medicine
Memorial University
St. Johns, NL

Suzanne Drodge is a Radiation Oncologist working with Eastern Health in St. John’s, NL, and an Assistant Professor with the Faculty of Medicine at Memorial University.   Her clinical sites include Thoracic and CNS malignancies.   She is also the physician lead for the dedicated palliative radiation oncology clinic and for the smoking cessation pilot clinic.  Currently, she is involved with CPAC as a member of the Pan-Canadian Tobacco Cessation and Cancer Care Network and a member of the Tobacco and Cancer Steering Committee.

Suzanne completed her Radiation Oncology residency and fellowship training at the University of Alberta.   She completed her Medical degree from Memorial University and has a Bachelor of Science degree in Cognitive Neuroscience from Brown University.

Peter Ellis, MBBS, MMed(Clin Epi), PhD, FRACP, FRCPC

Associate Professor, Dept. of Oncology & Clinical Epidemiology & Biostatistics
McMaster University
Medical Oncologists, Juravinski Cancer Centre
Hamilton, ON

Dr Ellis is an Associate Professor in the Departments of Oncology and Clinical Epidemiology & Biostatistics at McMaster University.  He is also a staff medical oncologist at the Juravinski Cancer Centre (JCC).  He obtained his medical degree at the University of Sydney. He completed a Masters of Medicine (Clinical Epidemiology) and a PhD also at the University of Sydney.  Dr Ellis moved to Canada in October, 2000.  He is the Chair of the JCC Lung Disease Site Team, an Executive Member of the National Cancer Institute of Canada (NCIC) Clinical Trials Group Lung Disease Site Committee, and is Co-Chair of Cancer Care Ontario’s Practice Guideline Initiative, Provincial Lung Disease Site Group.  He is also an investigator on several NCIC and pharmaceutical industry-sponsored multicentre phase III clinical trials in breast and lung cancer

Zsolt Gabos, MD, FRCPC

Radiation Oncologist, Cross Cancer Institute, Alberta Health Services
Associate Professor, Department of Oncology, University of Alberta
Edmonton, AB

Zsolt Gabos is an associate professor at the University of Alberta and a radiation oncologist at the Cross Cancer Institute.  His current practice focuses on the treatment of thoracic and breast malignancies. He is the clinical lead for the stereotactic body radiotherapy (SBRT) program at the Cross Cancer Institute and is the lung tumour group leader in Edmonton. He graduated from Radiation Oncology Residency at the University of Alberta and completed a fellowship in stereotactic radiosurgery and SBRT at the Tom Baker Cancer Centre, University of Calgary.

Daniel Glick, MD, FRCPC

Daniel Glick is a Clinical Instructor at the University of British Columbia and a radiation oncologist at the BC Cancer Agency Vancouver Island Centre. He currently treats lung and GI malignancies. He completed his medical school and radiation oncology residency training at the University of Toronto. His fellowship at Princess Margaret Cancer Centre focused on thoracic oncology and SBRT.

Glenwood Goss, MD, FCPSA, FRCPC

Glenwood Dillon Goss graduated from South Africa. He completed his post graduate training at the Royal Marsden Hospital in London, England. Dr. Goss is the Chair of the Thoracic Oncology Site Committee of the Canadian Cancer Trials Group, Professor of Medicine at the University of Ottawa, Directorof Clinical and Translational Research at the Ottawa Hospital Cancer Centre, member of the National Cancer Institute Thoracic Malignancy Steering Committee,a member of the Phase I Program at the Ottawa Hospital Cancer Centre, and a Clinical Investigator in the Ottawa Hospital Research Institute. He is the previous Division Head of Medical Oncology University of Ottawa, past member of the CCTG IND Executive and past Co-Chair of the Publications Committee of the International Association for the Study of Lung Cancer. He has over 300 publications in peer reviewed journals. His areas of interest are early cancer drug development and thoracic oncology.

Maher M. El-Masri, RN, PhD

Professor & Nursing Research Chair
University of Windsor Faculty of Nursing
Adjunct Professor, Department of Epidemiology & Biostatistics
Schulich’s School of Medicine & Dentistry, Western University
Editor, Canadian Journal of Nursing Research
Toldo Health Education Centre
Windsor, ON

Maher El-Masri is a full professor and Faculty Research Chair at the University of Windsor, Faculty of Nursing with an expertise in research methodology, biostatistics, and clinical epidemiology. He is the Editor-in-Chief of the Canadian Journal of Nursing Research (CJNR). He is also an adjunct professor at Western University, Schulich School of Medicine – Department of Epidemiology and Biostatistics; and is a visiting scholar with the College of Nursing and Professional Disciplines at the University of North Dakota.

During his academic tenure, Dr. El-Masri received a number of teaching and research awards that include the 2012 the Registered Nurses Association of Ontario Leadership in Nursing Research award, the University of Windsor’s Mid-career (2013) and emerging scholar (2006) awards. A Fulbright Scholar, Dr. El-Masri has published over 85 manuscripts that include peer reviewed research reports, book chapters, and short articles.

Desirée Hao, BA, MD, FRCPC

Medical Oncologist,
Associate Professor of Medicine, University of Calgary
Calgary, AB

After completing her MD at Queen’s University in Kingston, Ontario, Dr. Hao did her Internal Medicine residency in Calgary, her Medical Oncology training at the University of Ottawa, and a Clinical Research Fellowship in cancer drug development at the Institute for Drug Development in San Antonio, Texas. Dr. Hao joined the Tom Baker Cancer Centre / University of Calgary in December, 2001, and currently works in the Thoracic and Head & Neck Oncology Programs. She is active in both clinical and translational research for thoracic as well as head and neck malignancies. Dr. Hao is also a longstanding member of the Health Research Ethics Board of Alberta – Cancer Committee. She is Associate Professor of Medicine at University of Calgary where she is involved in teaching at all levels. In 2016, Dr. Hao joined the executive of the Canadian Association of Medical Oncologists (CAMO), a national specialty society of the Royal College of Physicians and Surgeons of Canada, committed to achieving and maintaining, among its members, excellence in clinical and scholarly activity. Dr. Hao currently serves as Treasurer (2016‐2018) within the CAMO executive, but will be transitioning in the spring into the role of Vice President (2018‐2020).

Felix J.F. Herth, MD, PhD, Dsc., FCCP, FERS

Chairman and Head Dep. of Pneumology and Critical Care Medicine Thoraxklinik University of Heidelberg
Heidelberg, GER

Felix JF Herth graduated at the University of Freiburg and was trained in Karlsruhe, Heidelberg, Germany and Boston, USA. Actual he is Professor of Pneumology at the University of Heidelberg.

His Department of Pulmonary and Respiratory Critical Care Medicine focuses on the diagnosis and therapy of respiratory tract diseases such as lung emphysema, cystic fibrosis, fibrosing alveolitis, and pulmonary hypertension; on non-invasive ventilatory support for patients with respiratory deficiency or failure; on sleep related respiratory disorders. An outstanding expertise is provided in all fields of bronchoscopy, taking a lead position in the development of devices for diagnostic and therapeutic purposes.

His research interest is Lung cancer, interstitial lung diseases and Interventional Bronchoscopy. Felix Herth is one of the European Health Leaders working closely with the European Heath commission.

Vera Hirsh, MD, FRCP(C)

Professor, Department of Medical Oncology
McGill University
Royal Victoria Hospital
Montreal, QC

Dr. Hirsh received her medical degree from Charles University in Prague, Czechoslovakia. She did a rotating internship and a two-year residency in Internal Medicine at Huntington Memorial Hospital – University of Southern California, U.S.A.

She then completed her residency in Hematology at the Royal Victoria Hospital – McGill University, Montreal, Canada. Her current practice includes both Hematology and Oncology. She is Chief of Hematology-Oncology Service at Santa Cabrini Hospital in Montreal.

She is also Associate Physician, Oncology Service, at the Royal Victoria and Montreal General Hospitals as well as Associate Professor of Oncology at McGill University. She has been chairing the Lung Cancer Committee of the McGill Department of Oncology since 1994. She has also chaired the Quebec Lung Cancer Committee to establish the guidelines for treatment of lung cancer.
She chaired five consecutive chemotherapy Phase I/II trials in lung cancer through the Quebec Pulmonary Unit and is chairing ongoing Quebec chemotherapy trials. She is a member of the Medical Oncology and Lung Cancer Core Committees of RTOG and the Data Safety Monitoring Board (DSMB) for all phase I and II trials.

She is a member of Editorial Boards for, Frontiers in Oncology and the World Journal of Clinical Oncology. She is a reviewer of many journals including Lung Cancer, Cancer, Clinical Lung Cancer and Annals of Oncology.

She is a member of global and national advisory boards for pharmaceutical companies. She was a chair of NCIC BR-14 Phase III trial comparing Platinum regimens with Gemcitabine/Vinorelbine in NSCLC Stage IIIB and IV.

She was a member of Steering Committees of international trials, i.e. AZ INTEREST trial, Roche CERA trial, Pfizer TLR-9 trial, Zephyr phase III trial, BIBW 2992 phase III third-line trial and is presently on Steering Committee of Sorafenib phase III trial, Pfizer phase III trial with ALK mutation agent, BIBW 2992 phase III first-line trial in lung cancer.

She has also authored over 200 publications which include articles, book chapters and abstracts.

Paris Ann Ingledew, MD, FRCPC, MHPE

Clinical Associate Professor, UBC Department of Surgery,
Division of Radiation Oncology and Developmental Therapeutics
Radiation Oncologist, British Columbia Cancer Agency
Vancouver, BC

Dr. Paris-Ann Ingledew is a Clinical Associate Professor in the UBC Department of Surgery and a Radiation Oncologist at the Vancouver Cancer Centre. She is the Undergraduate Division Director for Radiation Oncology & Developmental Radiotherapeutics at UBC.

She completed her MD and residency at the University of British Columbia.  She was a UBC Center for Health Education Scholarship (CHES) Fellow and she completed her Masters in Health Professions Education at the University of Illinois Chicago in 2013. Her current research interests are focused on the physician competencies related to patient education and projects related to oncology education in the undergraduate medical setting. She is the lead for a website used nationally and internationally in medical schools  Her clinical practice focuses on lung and breast malignancies.

Diana N. Ionescu, MD, FRCP(C), FCAP

Consultant Pathologist BC Cancer Agency Medical Director Clinical Trials, BCCA
Clinical Professor, Department of Pathology and Laboratory Medicine, UBC
AP Residency Program Director
University of British Columbia
Vancouver, BC

Dr. Ionescu is a graduate of University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj Napoca, Romania. She completed her postgraduate training in Anatomical and Clinical Pathology at the University of Pittsburgh Medical Center and a Fellowship in Gynecological Pathology at Vancouver General Hospital. She has practiced as a Consultant Pathologist at BC Cancer Agency in Vancouver since 2006. She is currently a Clinical Professor of Pathology at UBC and serves as the residency program director for the Anatomic Pathology Residency Program.

Her specific areas of diagnostic expertise are lung, gynecologic and breast pathology. She is an author of over 35 scientific publications and book chapters. She is the author and invited speaker at numerous regional, national and international lectures. Her investigation interests include oncologic pathology and molecular biomarkers, lung cancer and adult health education. She is the Canadian Anatomic and Molecular Pathology (CAMP) course director.

Dr. Ionescu is an enthusiastic advocate of pathologists participating in numerous patient education forums, TV shows, advocacy campaigns, being an Medical Advisor for Lung Cancer Canada and most recently appearing before the House of Commons Committee on Health.

David R. Jones, MD

Professor and Chief, Thoracic Surgery Service
Fiona & Stanley Druckenmiller Chair of Lung Cancer Research
Vice Chair Quality and Safety, Department of Surgery
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medical College
New York, NY

Dr. Jones graduated Phi Beta Kappa from West Virginia University and received his medical degree from West Virginia University School of Medicine where he was AOA. He completed his Thoracic Surgery Residency at the University of North Carolina at Chapel Hill, NC. In 1999, Dr. Jones joined the faculty at the University of Virginia where he became Professor and Vice-Chairman of the Department. In 2013 Dr. Jones was recruited to Memorial Sloan Kettering Cancer Center as Chief of Thoracic Surgery.

Dr. Jones is Professor & Chief of Thoracic Surgery at MSKCC and Vice-Chair of Quality in the Department of Surgery. He is also the Co-Director of the Fiona and Stanley Druckenmiller Center for Lung Cancer Research. Dr. Jones is Associate Editor for the Journal of Thoracic and Cardiovascular Surgery. He is recent past Chair of the NIH/NCI Tumor Progression and Metastasis (TPM) study section. He is Secretary-elect for the AATS and serves on numerous national and international committees related to thoracic surgical research and clinical care.

Dr. Jones’s research focuses on mechanisms and drivers of metastases in lung cancer. His research has been funded by the NIH/NCI, Department of Defense, and the AACR. He has been the Principal Investigator or Co-PI on over 28 funded grants and is currently R01-funded from the NCI. He has published over 260 papers and has written over 35 book chapters.

Keith Kerr, BSc, MBChB, FRCPath, FRCPE, FRCPI(FPath)

Consultant Pathologist, Aberdeen Royal Infirmary
Aberdeen, UK

Keith Kerr is a consultant pathologist for NHS Grampian, based at Aberdeen Royal Infirmary and Hon Professor of Pulmonary Pathology at Aberdeen University Medical School. After medical school and post-graduate training at the University of Edinburgh, he has worked as a diagnostic pathologist with a special interest in thoracic pathology whilst maintaining an active research programme, primarily in lung cancer. He works in various roles for IASLC, ESMO and ETOP. He has been closely involved in the evolution of biomarker testing in lung cancer and contributed to the WHO lung cancer classification and several lung cancer diagnostic/management guidelines.

Suneil Khanna, MD FRCPC

Clinical Lecturer, University of Toronto
Medical Oncologist, Mackenzie Health Hospital
Richmond Hill, ON

Suneil Khanna is a Medical Oncologist at Mackenzie Health Hospital in Richmond Hill ON. Dr. Khanna completed medical school at the University of Alberta and residency in internal medicine and medical oncology at the University of Calgary. He then completed a fellowship in Gastrointestinal and Thoracic Malignancies at Sunnybrook Health Sciences Centre in Toronto.

Dr. Khanna completed the Master Teacher Program through the University of Toronto. He is currently on the organizing committee for the Multidisciplinary Annual GI Conference (MAGIC) and is the co-educational lead of the Community Oncologists of Metropolitan Toronto (COMET).

Noriaki Kurimoto

Professor, Department of Medical Oncology and Respiratory Medicine
Shimane University Hospital
Izumo, Japan

Dr. Kurimoto is Professor of Department of Medical Oncology and Respiratory Medicine, Shimane University Hospital. He is a distinguished scientist in the field of bronchology. Dr. Kurimoto’s research interest is in EBUS, bronchoscopic diagnosis and treatment of lung cancer. He was the recipient of the Ikeda Award and Ohata Award by Japan Society for Respiratory Endoscopy.

Stephen Lam, MD, FRCPC

Professor of Medicine, Respiratory Division, UBC
Chair, Lung Tumour Group, BC Cancer Agency
Vancouver, BC

Dr. Lam is Professor of Medicine at UBC in the Respiratory Division. He is currently Chair of the Lung Tumour Group and directs the MDS-Rix Early Lung Cancer Detection and Translational Research Program at the BC Cancer Agency. He is a Distinguished Scientist in the Department of Integrative Oncology at the BC Cancer Research Centre. Dr. Lam’s research interest is in early detection, chemo prevention, endoscopic diagnosis and treatment of lung cancer. He was the recipient of the Joseph Cullen Award for life – time scientific achievements in lung cancer prevention research by the International Association for the Study of Lung Cancer and the UBC Killam Award.

Percy Lee, MD

Associate Professor & Vice Chair of Education,
Department of Radiation Oncology, David Geffen School of Medicine
Director, Stereotactic Body Radiation Therapy Program
Los Angeles, CA

Dr. Percy Lee is an Associate Professor and Vice Chair of Education for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center. He serves as the Residency Training Program Director as well as the Director for the Medical Student Clerkship. Dr. Lee attended the Johns Hopkins University and graduated with the highest honors majoring in Biomedical Engineering with a concentration in Chemical Engineering. He attended Harvard Medical School and the Harvard-MIT Health Science and Technology program (HST) where he received his M.D., and graduated Magna cum laude. At Harvard, he was also a Howard Hughes Medical Institute fellow. He interned at the Massachusetts General Hospital and received specialty training in Radiation Oncology from Stanford University School of Medicine. Dr. Lee is the Clinical Director of the Stereotactic Body Radiation Therapy (SBRT) program and the Chief of Service for the Thoracic and GI Radiation Oncology programs in the department.

Natasha B Leighl, MD, MMSc, FRCPC

Medical Oncologist, Princess Margaret Hospital
Associate Professor, Department of Medicine
University of Toronto
Toronto, ON

Dr. Natasha Leighl is a medical oncologist at the Princess Margaret Hospital, Toronto, Canada, and Associate Professor in the Department of Medicine at the University of Toronto, Toronto, Canada.

After receiving her MD from the University of Toronto, Dr. Leighl completed residencies in internal medicine at the University of Calgary and in medical oncology at the University of Toronto. She subsequently completed a Fellowship in Thoracic Oncology with Dr Frances Shepherd at the Princess Margaret Hospital, a Fellowship in Clinical Oncology with Professor Martin Tattersall at the University of Sydney, Australia, and received her MMSc in Clinical Epidemiology at the University of Newcastle, Australia.

Dr. Leighl’s main interest is in developing new treatments in lung cancer. She is a member of the Lung Disease Site Executive and co-chairs the Committee on Economic Analysis in the NCIC Clinical Trials Group. Dr. Leighl is currently Web Editor of the Journal of Thoracic Oncology, Section Co-Editor of The Oncologist and Current Oncology and a member of the editorial board of the Journal of Clinical Oncology. She has served on several committees including as Lung Track Leader for the American Society of Clinical Oncology (ASCO) Cancer Education Committee, the Royal College of Physicians and Surgeons of Canada Medical Oncology Examination Board and the International Association for the Study of Lung Cancer (IASLC) Career Development and Continuing Education Committees. She is currently President of Lung Cancer Canada and has recently been awarded the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development at the University Health Network, University of Toronto.

Bonnie Leung, NP

Vancouver, BC

Bonnie Leung is a nurse practitioner at the British Columbia Cancer Agency in Vancouver, Canada.  She completed her Masters in Nursing at the University of Victoria in British Columbia. She is a part of an interdisciplinary team, working alongside medical and radiation oncologists in the care of patients with lung cancer and head and neck cancers

Alex Louie, MD, PhD, MSc, FRCP(C)

Assistant Professor and Clinician-Scientist, Western University
Radiation Oncologist, London Regional Cancer Program
London, ON

Dr. Alex Louie is a Radiation Oncologist at the London Regional Cancer Program and a Clinician-Scientist at Western University. Following his residency at the same institution, he obtained a Master’s Degree in Epidemiology from the Harvard School of Public Health, and a PhD cum laude from the VU University Medical Center (Netherlands). He is cross-appointed in Epidemiology at Western, is a faculty scholar of the Institute for Clinical Evaluative Sciences and is a recipient of the inaugural IASLC academy award program.

Dr. Louie’s lung cancer research focuses on patient reported outcomes, economic evaluations, population analyses, comparative effectiveness and clinical trials. Under the auspices of the Canadian Pulmonary Radiotherapy Investigators ( group, he is the PI of a phase III trial evaluating the use of esophageal sparing IMRT for advanced lung cancer patients.

Leslie Markin, RN

Clinical Trials Nurse Coordinator, BCCA
Vancouver, BC

Leslie Markin is a Clinical Trials Nurse Coordinator for the Lung Tumor Group at BC Cancer in Vancouver, Canada. She graduated from University of Alberta Hospital School of Nursing and previously worked in ER and Ambulatory Care Chemotherapy Unit.

Leane Mathias, NP, BScN

Family Nurse Practitioner, Vancouver Coastal Health
North Shore Palliative Care
Vancouver, BC

Leane Mathias graduated from the Bachelor of Science in Nursing Program at UBC in 1999 and the Family Nurse Practitioner Program at UVic in 2014.

Her nursing experience was in pediatric and adult oncology and palliative care in both Vancouver and Australia.

For the past three years, Leane has been working as a nurse practitioner in the community on the North Shore, providing symptom management and end-of-life care for patients registered on the North Shore Palliative Care Program.

Drew Moghanaki, MD, MPH

Radiation Oncologist & Director, Clinical Radiation Oncology Research
Veterans Affairs Medical Centre
Richmond, VA

Dr. Drew Moghanaki is the Director of Clinical Radiation Oncology Research at the Veterans Affairs Medical Center in Richmond, Virginia. He is currently the co-chair of the Veterans Affairs phase III clinical trial that is evaluating the role of stereotactic radiotherapy as an alternative to surgery for lung cancer patients. He is also a member, advisor, and chair of multiple committees for national organizations in the US that includes the American Cancer Society, American Society of Radiation Oncology, the Lung Cancer Alliance, and the Lungevity Foundation. He has received over $34 million in funding for national lung cancer research and implementation projects that have a focus on early detection and treatment of patients with early stage disease. This includes a partnership that he’s developed between the VA and the International Early Lung Cancer Action program to decrease the mortality of lung cancer among US Veterans.

Massey Nematollahi, RN, MscN, OCN®,CON(c)

Oncology Clinical Trials Coordinator, Stronach Regional Cancer Center
Chair, Lung Nurses Network of Lung Cancer Canada
Southlake, ON

Massey is an oncology clinical trials coordinator at Stronach Regional Cancer Center at Southlake ,Ontario.

A joint clinical appointee at the Lawrence S. Bloomberg Faculty of nursing at University of Toronto, Massey received her certificate in immunotherapy from the Oncology Nursing Society (ONS). She is a member of the international Association for the Study of Lung Cancer (IASCL) , as steering committee member at ITONF (International Thoracic Oncology Nursing Forum ), and a member of the Society for Immunotherapy of Cancer (SITC).

Massey chairs the Lung Nurses Network of Lung Cancer Canada and has been elected to chair the World Lung Cancer Congress, Nursing and Allied Health track 2018 which will be held in Toronto.

Recognized for her outstanding achievements by CANO, CCO and ONS, Massey lectures nationally and internationally on lung cancer , immunotherapy and cancer patient education.

Jason Pantarotto, MD, FRCPC

Associate Professor of Radiology, University of Ottawa
Radiation Oncologist, The Ottawa Hospital Cancer Program
Ottawa, ON

Jason Pantarotto is the Head of the Radiation Medicine Program at The Ottawa Hospital and Division Head for Radiation Oncology at the University of Ottawa.

His education includes a degree in Applied Science from Queen’s University, a medical degree from Western University, a residency in Radiation Oncology from the University of Ottawa and a fellowship at the VUMC Amsterdam, The Netherlands. Dr. Pantarotto is a graduate of the Physician Leadership Development Program at the Schulich School of Business.

Dr. Pantarotto has published on ablative radiotherapy for chest and abdominal tumours, advanced radiotherapy techniques for moving targets and factors related to process flow within radiation medicine. He treats lung and GI malignancies and has served as the Medical Director for CyberKnife in Ottawa since 2010.

Dr Sanjay Popat, FRCP, PhD

Consultant Medical Oncologist, Royal Marsden Hospital
Reader in Cancer Medicine, Imperial College London
London, UK

Sanjay is an internationally recognized expert in the treatment of thoracic malignancies. He Chairs the British Thoracic Oncology Group (BTOG), and is Chair of the Advanced Diseases Sub-group of the UK NCRI Lung Cancer Clinical Studies Group. He has been elected onto the Foundation Council of the European Thoracic Oncology Platform (ETOP) where he is CI of the 9-15 (PROMISE-Meso) trial, is active in the European Organization for Research and Treatment of Cancer (EORTC) Lung Group- where he is CI of the EORTC 08114 (GEM) and 08112 (NEMO) studies- and the International Thymic Malignancy Interest Group (ITMIG). He qualified from Guy’s and St Thomas’ Hospitals in 1994 with triple distinction, the Solly Prize and Medal, and a First Class BSc in Experimental Pathology. He was awarded a PhD in Molecular Genetics in 2002 and has been awarded nationally and internationally competitive prizes for his research, in addition to 4 research fellowships.

Randeep Sangha, MD, FRCPC

Medical Oncologist, Cross Cancer Institute
Assistant Professor, University of Alberta
Edmonton, AB

Dr. Sangha is an Associate Professor in the Department of Oncology at the University of Alberta and Medical Oncologist at the Cross Cancer Institute, Edmonton, AB. He is the Provincial Lead for the Alberta Lung Cancer Program.

Dr. Sangha received his medical degree at the University of Alberta and subsequently specialized in Internal Medicine and Medical Oncology. He completed two years of post-fellowship training in thoracic oncology at the University of California, Davis Comprehensive Cancer Center.

His academic, clinical, and educational activities revolve around thoracic and hematological malignancies. He is also experienced in Investigational New Drug (Phase I) development and is actively involved in the Phase I clinical trials program at the Cross Cancer Institute.

Dr. Alexander Sun, MD, FRCPC

Associate Professor, University of Toronto, Department of Radiation Oncology
Radiation Oncologist, Princess Margaret Cancer Centre
Principal Investigator – RTOG/NRG Oncology
Lung Cancer Site Group Leader, RMP
Toronto, ON

Dr. Alex Sun is an Associate Professor at the University of Toronto, Department of Radiation Oncology. He is a Radiation Oncologist at the Princess Margaret Cancer Centre and is the Lung Cancer Site Group Leader, Radiation Medicine Program. His research interests include clinical trials in lung cancer and he is the Lead Principal Investigator of RTOG/NRG Oncology at Princess Margaret Cancer Centre. His lung cancer research interests include the incorporation of metabolic imaging in the management of lung cancer patients. He is the Principal Investigator of the PET Boost trial, a prospective randomized trial with the addition of FDG-PET imaging to boost the radiation dose in locally advanced non-small cell lung cancer (LA-NSCLC). He is also leading another prospective study with FAZA-PET imaging in LA-NSCLC, examining the addition of FAZA, a hypoxic PET tracer.

His other research interests include the addition and combination of immunotherapy and radiotherapy. He will be leading a prospective study of immunotherapy combined with thoracic radiotherapy in patients with advanced NSCLC. He is also interested in radiomics. Radiomics is an emerging field of research aimed at using computational techniques to extract the most informative features from radiological images routinely used in clinical settings. Recent studies in patients with lung cancer have demonstrated the effectiveness of radiomic features as biomarkers of clinical outcome after treatment with definitive/curative radiotherapy. His other area of interest is the role of Prophylactic Cranial Irradiation (PCI) in NSCLC and SCLC. He has lead multiple clinical trials including Co-PI of RTOG 0214, RTOG 0937 and NRG CC003. He has published manuscripts in journals such as Lancet Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, IJROBP, Radiotherapy and Oncology among others.

Anand Swaminath, MD, FRCPC

Associate Professor, Department of Oncology, McMaster University
Clinician Scientist and Radiation Oncologist, Juravinski Cancer Centre
Hamilton, ON

Dr. Swaminath is a Clinician Scientist & Radiation Oncologist at the Juravinski Cancer Centre, Associate Professor in the Department of Oncology at McMaster University, and Associate Scientist at the Escarpment Cancer Research Institute in Hamilton, Ontario. His main clinical interests are in the treatment of lung, hepatobiliary, and kidney cancers, with a focus on use of ablative radiotherapy directed at primary lung/liver/kidney cancer and oligometastatic disease. His research interests are mainly in evaluation of new technologies in radiotherapy delivery, within the context of transdisciplinary clinical trials. He is primary or co-investigator on several research projects assessing the effectiveness of high precision/stereotactic radiotherapy in lung, breast, and GU cancers. He is also involved at the provincial level on the Cancer Care Ontario lung disease site group, lung communities of practice (with interest in peer review and quality assurance) and Ontario PET Steering Committee.

Devin Schellenberg, MD, FRCS(C)

Clinical Instructor, Radiation Oncologist
Department of Radiation Oncology
BC Cancer Agency, Abbotsford Centre & Fraser Valley Centre
Vancouver, BC

Dr. Devin Schellenberg is a radiation oncologist practicing in the Fraser Valley and Abbotsford Cancer Centres. He is currently the head of the Clinical Trials Unit at the Abbotsford Cancer Centre and is one of the leaders in the British Columbia stereotactic radiation working group.

His radiation oncology residency was carried out at Princess Margaret Hospital in Toronto and the BC Cancer Agency, after which he completed a fellowship in stereotactic body radiation therapy at Stanford University in 2007.

His present research is focused on the use of novel imaging modalities in radiation therapy.

Paul Wheatley-Price BSc, MBChB, FRCP (UK), MD

Medical Oncologist, The Ottawa Hospital Cancer Centre
Assistant Professor, Department of Medicine
University of Ottawa
Ottawa, ON

Dr Paul Wheatley-Price has been a medical oncologist at The Ottawa Hospital Cancer Centre since 2009, specializing in the treatment of thoracic malignancies, and is Assistant Professor in the Department of Medicine at the University of Ottawa. He is Deputy Division Head in Medical Oncology, and since 2016 has been President of Lung Cancer Canada.

Dr Wheatley-Price attended medical school in the UK, at the University of St. Andrews (1991-1994) and the University of Manchester (1994 – 1997). He received specialist medical oncology training in Wellington, New Zealand, in London at the Royal Free Hospital, Guy’s and St. Thomas’ Hospitals and St. George’s Hospital, and subsequently as Oberlander Fellow in Lung Cancer Research at Princess Margaret Cancer Centre, Toronto, under the supervision of Dr. Frances Shepherd.

His research interests are in thoracic oncology, with an emphasis on systemic therapy in challenging clinical scenarios, and in the rare cancer types mesothelioma and thymoma.  He has won teaching and presentation awards at the University of Ottawa.

He is active in lung cancer advocacy, in June 2016 becoming President of Lung Cancer Canada, a national charity supporting patient and caregivers lung cancer, and promoting advocacy and research.

Annick Wong MD, BSc, FRCPC

Medical Oncologist, McGill University Hospital Centre
Associate Professor, McGill University
Montreal, QC

Dr. Annick Wong is a medical oncologist at the McGill University Hospital Centre (MUHC). She participates in the Multidisciplinary Lung Cancer Clinic, Thoracic Tumor Board and clinical trials. She is an Adjoint Professor at McGill University. She also practices at CSSS du Suroît where she is the chief of the Medical Oncology department. She completed her BSc in Honors Biology at McGill University before getting her medical degree at Université de Montréal. She completed her Internal Medicine degree at McGill University and her Medical Oncology fellowship at Mcgill University and the Jewish General Hospital.

John Yee, MD, FRCS(C)

Assistant Professor- Division of Thoracic Surgery, UBC
Director- Lung Transplant Program, VGH
Vancouver, BC

Dr. John Yee is an Assistant Professor-Division of Thoracic Surgery, UBC and Director- Lung Transplant Program, VGH.

Dr. Yee is a designate of the Chair of the UBC Department of Surgery for the Surgical Oncology Network Council Executive.

Xiaofu Zhu, MD FRCPC

Medical Oncologist
Cross Cancer Institute
Edmonton, AB

Dr. Zhu is an assistant professor at University of Alberta in Edmonton, Alberta. He graduated from medical school at University of Western Ontario (now Western University), followed by residency training in internal medicine and medical oncology at University of Ottawa, and fellowship training at University of Toronto. He is a staff medical oncologist at Cross Cancer Institute in Edmonton. He is also one of two medical oncologists from Alberta to participate in a satellite clinic in Yellowknife, NWT, which provides medical consultation and treatment closer to home for patients in the vast far north. His clinical interest and experience include a number of malignancies, including breast, gynecologic, and thoracic cancers.

Kelly Zibrik, MScN, RN

Coordinator, Lung Tumor Group
BC Cancer Agency
Vancouver, BC

Kelly Zibrik received her Bachelor in Science in Nursing degree from the University of British Columbia in 2002 and a Masters degree in Nursing from the University of Northern British Columbia in 2009. She has worked at the BC Cancer Agency since 2004 in various clinical nursing roles and is currently working as a nurse triage coordinator with the lung tumor group at the Vancouver Centre.